GW Pharmaceuticals Plc.

GW Pharmaceuticals Plc. (NASDAQ:GWPH)
GWPH
GW2A

GW Pharmaceuticals Plc. (NASDAQ:GWPH) (FRA:GW2A) is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW Pharmaceuticals, along with its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA approval for EPIDIOLEX (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older, pending DEA rescheduling. GW Pharmaceuticals has submitted a regulatory application in Europe for the adjunctive treatment of LGS and Dravet syndrome. The company continues to evaluate EPIDIOLEX in additional rare epilepsy conditions and currently has ongoing clinical trials in tuberous sclerosis complex (TSC) and infantile spasms (IS). GW Pharmaceuticals commercialized the worldโ€™s first plant-derived cannabinoid prescription drug, Sativexยฎ (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a U.S. Phase 3 trial. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia. For further information, please visit www.gwpharm.com.

SP4 0JQ
https://www.gwpharm.com/
United Kingdom

Ratings

There are no reviews yet.

Post your review

Directions to listing

Send Message to listing owner

GW Pharmaceuticals Plc.